Viking Therapeutics advances 3 obesity trials with $502M cash runway

Viking Therapeutics Inc. said its two Phase 3 obesity trials for subcutaneous VK2735 are fully enrolled, while maintenance dosing data and an oral formulation study timeline both fall in the second half of 2026.

"2025 was an exceptional year for Viking marked by rapid progress across our obesity portfolio," Chief Executive Officer Brian Lian said in a statement. "We are now executing across three clinical-stage programs, including the initiation of a Phase 1 study for our novel amylin agonist VK3019."

The San Diego-based biotech reported $502 million in cash at the end of the second quarter, down from roughly $706 million at year-end 2025 as research spending accelerated. The company posted a net loss of $157.66 million in the fourth quarter of 2025, with full-year research and development costs more than tripling to $344.95 million as it scaled its obesity pipeline.

VK2735, a dual GLP-1/GIP agonist, is Viking's lead candidate in a weight-loss drug market dominated by Eli Lilly & Co. and Novo Nordisk A/S. The VANQUISH-1 trial enrolled more than 4,500 patients, and Phase 2 oral data from the VENTURE study showed up to 12.2% mean body weight reduction after 13 weeks. The company expects to begin oral Phase 3 dosing in the fourth quarter and report maintenance dosing results in the third quarter. A Phase 1 study of VK3019, an amylin agonist that represents a distinct mechanism from the GLP-1 class, is already underway.

Competitive Positioning and Cash Runway

Viking's dual formulation strategy — a monthly subcutaneous injection alongside daily or weekly oral dosing — could differentiate it against the Lilly-Novo duopoly if Phase 3 data mirrors the Phase 2 results. But the company remains pre-revenue with an escalating burn rate, making the upcoming data readouts binary events for the stock.

Analysts see significant upside if the trials succeed. The consensus price target of $92.58 implies 175% upside from the current $33.38, with 90% of analysts rating the stock a buy and none recommending a sell. Shares have fallen about 16% over the past month as sentiment around the obesity pipeline reset.

The company's $502 million cash position provides runway through multiple data readouts, reducing near-term dilution risk. But the cash burn is accelerating: fourth-quarter 2025 operating expenses consumed $157.66 million, and full-year R&D spending more than tripled to $344.95 million as Viking scaled manufacturing and clinical operations.

What's at Stake

The obesity drug market represents a tens-of-billions-dollar opportunity, with some analysts projecting peak sales exceeding $100 billion annually by the early 2030s. Lilly's Zepbound and Novo's Wegovy already generate combined annual revenue above $30 billion. Viking's VK2735, if approved, would enter a market where demand continues to outstrip supply, but the company would need to demonstrate a clear efficacy, tolerability, or dosing advantage to capture meaningful share against well-capitalized incumbents.

The next catalyst cascade is dense: Moderna Inc.'s Aug. 5 FDA decision on its seasonal flu vaccine will test the broader biotech risk appetite, while Viking's own maintenance dosing data in the third quarter and oral Phase 3 initiation in the fourth quarter will determine whether the stock can close the gap to its analyst targets.

This article is for informational purposes only and does not constitute investment advice.